Term ended Feb 3, 2026 · High confidence
20-year base term ended Feb 3, 2026
Held by Intarcia Therapeutics, Inc.
Filed Apr 22, 2008 as application 12/148,896 · Granted Oct 30, 2012
Base term plus 164 days of patent term adjustment (USPTO delay) · capped by a resolved terminal disclaimer
Today
Term ended Feb 3, 2026
2006
2026
Clock starts
Feb 3, 2006
Feb 3, 2006
Term ended
Feb 3, 2026
Feb 3, 2026
Granted
Oct 30, 2012
Oct 30, 2012
base term
after the term ends
fee events
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
164
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
Capped
Terminal disclaimer
Resolved from the filed document, referencing US 8,114,437, US 8,206,745.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
23
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term runs 164 days past its 20-year base term on prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. All three maintenance fees were paid, so no fee lapse ended it. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Feb 3, 2006, when application 11/347,562, the earliest non-provisional in its chain, was filed (this one was filed Apr 22, 2008) | Feb 3, 2026 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +164 days, USPTO patent term adjustment record | Jul 17, 2026 | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 8,114,437, US 8,206,745) | capped to Feb 3, 2026 | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | term ended | High confidence |
| Computed term end | The steps above, in order | Feb 3, 2026 | High confidence |
This family
| US 8,114,437 | In force Aug 2027 | Aug 2027 |
| US 8,052,996 | In force no later than Feb 2029 | no later than Feb 2029 |
| US 8,299,025 | this patent Feb 2026 | Feb 2026 |
| US 8,211,467 | Term ended Feb 2026 | Feb 2026 |
| US 8,940,316 | In force no later than Jan 2029 | no later than Jan 2029 |
| US 8,206,745 | Term ended Feb 2026 | Feb 2026 |
| US 8,158,150 | Term ended Feb 2026 | Feb 2026 |
| US 8,273,365 | Term ended Feb 2026 | Feb 2026 |
8 of 23 applications in this family shown, earliest filings first. Every application listed has its file history here. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jun 12, 2008 Reel 21093, frame 549 | Alessi, Thomas R.; Mercer, Ryan D.; Rohloff, Catherine M.; Yang, Bing | Intarcia Therapeutics, Inc. | Assignment of Assignor's Interest |
| Sep 8, 2010 Reel 24953, frame 525 | Intarcia Therapeutics, Inc. | Oxford Finance Corporation; Silicon Valley Bank | Security Agreement |
| Sep 8, 2010 reel/frame not recorded | Intarcia Therapeutics, Inc. | Oxford Finance Corporation | Security Agreement |
| Sep 8, 2010 reel/frame not recorded | Intarcia Therapeutics, Inc. | Silicon Valley Bank | Security Agreement |
| May 13, 2011 Reel 26279, frame 629 | Alessi, Thomas R.; Mercer, Ryan D.; Rohloff, Catherine M.; Yang, Bing | Intarcia Therapeutics, Inc. | Assignment of Assignor's Interest |
| Sep 23, 2011 Reel 26962, frame 62 | Oxford Finance Corporation; Silicon Valley Bank | Intarcia Therapeutics, Inc. | Release of Security Interest |
| Nov 14, 2012 Reel 29299, frame 678 | Intarcia Therapeutics, Inc. | U.S. Bank National Association, as Collateral Agent | Security Agreement |
| Oct 23, 2015 Reel 36942, frame 544 | U.S. Bank National Association, as Collateral Agent | Intarcia Therapeutics, Inc. | Release of Security Interest |
| Oct 9, 2019 Reel 50673, frame 20 | Intarcia Therapeutics, Inc.; Intarcia Ireland Limited | Midcap Financial Trust, As Agent | Security Interest |
| Oct 23, 2019 Reel 50801, frame 267 | Intarcia Therapeutics, Inc. | Baupost Private Investments Bviv-3, L.L.C., as Collateral Agent | Security Interest |
| Jan 29, 2020 Reel 51739, frame 453 | Baupost Private Investments Bviv-3, L.L.C. as Collateral Agent | Intarcia Therapeutics, Inc. | Release of Security Interest |
| Apr 17, 2020 Reel 52433, frame 1 | Midcap Financial Trust, As Agent | Intarcia Therapeutics, Inc.; Intarcia Ireland Limited | Release of Security Interest |
| Apr 17, 2020 reel/frame not recorded | Midcap Financial Trust, As Agent | Intarcia Therapeutics, Inc. | Release of Security Interest |
| Apr 17, 2020 reel/frame not recorded | Midcap Financial Trust, As Agent | Intarcia Ireland Limited | Release of Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Note
The 164 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Disclaimer cap
This term is capped by a terminal disclaimer resolved from the filed document, referencing US 8,114,437, US 8,206,745.
Citations
243
later US patents cite this one
That is top 5% of utility patents granted in 2012 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.